Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach.
about
Macrophage Heterogeneity and Plasticity: Impact of Macrophage Biomarkers on AtherosclerosisPsoriasis and comorbid diseases: Epidemiology.Diet and dermatology: the role of dietary intervention in skin diseasePathogenic mechanisms shared between psoriasis and cardiovascular diseaseComorbidities and cardiovascular risk factors in patients with psoriasis.Psoriasis and comorbidities: links and risks.Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis.Cardiovascular comorbiditiy in psoriasisPrevalence of cardiovascular disease risk factors, and metabolic syndrome and its components in patients with psoriasis aged 30 to 49 yearsChronic skin-specific inflammation promotes vascular inflammation and thrombosis.Improving cardiovascular health and metabolic comorbidities in patients with psoriatic arthritisPsoriatic arthritis and diabetes: a population-based cross-sectional studyEfficacy of adding topical simvastatin to topical calcipotriol on improvement of cutaneous plaque psoriasisThe latest advances in pharmacogenetics and pharmacogenomics in the treatment of psoriasis.Psoriasis and obesity: literature review and recommendations for management.Alpha7 nicotinic receptors as novel therapeutic targets for inflammation-based diseases.A tale of two plaques: convergent mechanisms of T-cell-mediated inflammation in psoriasis and atherosclerosis.The concept of psoriasis as a systemic inflammation: implications for disease management.Inflammation, atherosclerosis, and psoriasis.Cardiovascular aspects of psoriasis: an updated review.Rational for statin use in psoriatic patients.Impact of smoking on response to systemic treatment in patients with psoriasis: a retrospective case-control study.Childhood-onset psoriasis: association with future cardiovascular and metabolic comorbidities.Psoriasis and the liver: problems, causes and course.Serum YKL-40 as a potential biomarker of inflammation in psoriasis.Prevalence of Metabolic Syndrome in Patients with Mucosal Lichen Planus: A Case-Control Study.Association of chronic plaque psoriasis and severe periodontitis: a hospital based case-control study.Prevalence and extent of subclinical atherosclerosis in patients with psoriasis.Profile of patients with psoriasis associated with hepatitis C virus infection.Plasmin induces intercellular adhesion molecule 1 expression in human endothelial cells via nuclear factor-κB/mitogen-activated protein kinases-dependent pathways.Psoriasis and Cardiovascular Comorbidities: Focusing on Severe Vascular Events, Cardiovascular Risk Factors and Implications for Treatment.The impact of biologic agents on health-related quality of life outcomes in patients with psoriasis.Expression of low-density lipoprotein-related receptors 5 and 6 (LRP5/6) in psoriasis skin.Serum levels of psoriasin (S100A7) and koebnerisin (S100A15) as potential markers of atherosclerosis in patients with psoriasis.Atorvastatin for the treatment of plaque-type psoriasis.Metabolic syndrome in psoriatic arthritis patients: a cross-sectional study.Impact of adalimumab treatment on cardiovascular risk biomarkers in psoriasis: Results of a pilot study.Serum paraoxonase-1 activities and oxidative status in patients with plaque-type psoriasis with/without metabolic syndrome.Systemic Inflammation and Cardiovascular Comorbidity in Psoriasis Patients: Causes and Consequences.Unmet Needs in the Field of Psoriasis: Pathogenesis and Treatment.
P2860
Q26780531-4DFA4EB1-E18E-4370-A929-FE3AF4D5E1C7Q30235889-1919CD26-DF5D-4E1B-A59C-3C1F506B96C1Q33931312-5269B936-7478-48AD-8034-9EFCFF12C9CCQ34107573-41C7DB58-A2A0-4FB9-A9A7-32ECE7454424Q34140480-A792784E-6409-45F8-B431-062E9B789B73Q34418506-AABB55CA-65AE-443B-85C9-D40F2F9B636FQ35285238-2590BE8E-182C-4A6D-85F3-738CF7422D56Q35564655-165D181E-6F0A-4066-B6AB-D4F4BCCD5BC3Q36048427-A2B5F8D3-CD8E-414D-8660-6A96B015DCBDQ36110025-1F6ADDB2-3394-42AD-AD27-217B3A24CAC5Q36843650-FCA9E74E-911E-4E69-B546-CE1F75F6C823Q36988417-8B699610-73BB-4327-A2CF-A24C9D5B09DCQ37592632-B1DB8DBC-2252-437D-8DDC-6F67F17E4508Q37722744-A5F1AF62-D1B7-4466-80DD-E8A67E8E003EQ37777037-2252CDF7-2F3A-4394-BD04-151C2AD45A32Q37800819-1C1A447E-C3AB-45A0-A62E-213E843245EEQ37892623-C9F491B0-F6A3-4CE0-9C44-07A1888025EAQ37987268-4C6ACC38-5F19-4D3E-9D4B-2BBEA95EEAB5Q37987473-4F9EF49A-838F-4549-8D19-166BA36FD218Q38076496-E15C995E-DB80-45E4-AA10-A1800D747062Q38113531-67155175-0BFC-442A-96C9-F686922DB5F6Q38241734-BFB39EF5-8C4D-45BF-A48F-3DB3CCABCA4FQ39368379-FD9D2935-DAAC-4F53-A284-69621477131CQ39967628-1B42C8AF-967F-405B-B486-49D782D1E77CQ40215575-9EC9E310-8AFA-44B3-97C1-C446462099D4Q41582154-3C3F5EB7-111E-4D88-9743-22A6419B001CQ43481799-AC9C2F99-1E76-4F02-B410-FA0AAD50CD1CQ45249524-92CB4C66-34BF-407D-A560-89F2D062280DQ45352573-33AD96FD-524D-4BDD-87D2-C867D33E4E53Q46122228-639F7D3D-8163-4F17-BF9A-A6FC79C7CFFDQ46180528-07E9FF7C-A137-4E01-8BED-0C7F64DF8312Q47644680-A2FE06F7-4F9B-4086-8F8D-B5A0451BF467Q48265578-C82F379A-D4B7-4DB0-B547-AAFCF4FD60A5Q50048507-0D647104-E815-4D2B-AEC1-9821CB96B06FQ50998182-3B6A949E-A5A2-405A-8135-77052F4E9CFDQ51329205-2B916E95-C764-4EBD-B095-478B46B06ABAQ51367320-415AD2B6-14BD-4A64-8B3A-7CA5B8882D9BQ51370354-AF1A52A4-9022-4C8A-BE9B-7D663CFEF338Q52314887-C653D910-1AD7-450E-A875-50AAA069E4ACQ53123754-185A7B7A-6EB4-40CB-944F-DFDF0A4F6693
P2860
Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Inflammation in atherosclerosi ...... integrated treatment approach.
@en
Inflammation in atherosclerosi ...... integrated treatment approach.
@nl
type
label
Inflammation in atherosclerosi ...... integrated treatment approach.
@en
Inflammation in atherosclerosi ...... integrated treatment approach.
@nl
prefLabel
Inflammation in atherosclerosi ...... integrated treatment approach.
@en
Inflammation in atherosclerosi ...... integrated treatment approach.
@nl
P2860
P1476
Inflammation in atherosclerosi ...... integrated treatment approach.
@en
P2093
P2860
P356
10.1111/J.1365-2133.2008.08780.X
P407
P478
159 Suppl 2
P577
2008-08-01T00:00:00Z